MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
Seeking Alpha5/13/2026Neutral
MXCT
MaxCyte IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$138.19M
P/E Ratio
—
EPS
$-0.37
Beta
1.66
52W High
$2.37
52W Low
$0.64
50-Day MA
$1.08
200-Day MA
$1.20
Dividend Yield
—
Profit Margin
-121.20%
Forward P/E
—
PEG Ratio
—
About MaxCyte Inc
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Fundamentals
| Revenue (TTM) | $32.29M |
| Gross Profit (TTM) | $25.99M |
| EBITDA | $-34.16M |
| Operating Margin | -64.10% |
| Return on Equity | -21.30% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $1.57 |
| Price-to-Book | 0.78 |
| Price-to-Sales (TTM) | 4.28 |
| EV/Revenue | 1.263 |
| EV/EBITDA | -11.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.10% |
| Shares Outstanding | $107.12M |
| Float | $97.63M |
| % Insiders | 1.59% |
| % Institutions | 67.92% |
Historical Volatility
HV 10-Day
43.36%
HV 20-Day
49.47%
HV 30-Day
58.80%
HV 60-Day
71.57%
HV Rank
27.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.11 target)
5
Buy2
HoldLatest News
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.
GlobeNewsWire5/12/2026Neutral
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
GlobeNewsWire4/29/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026